COMPASS Pathways plc
No SEC Form 4 filings for $CMPS in the last 30 days.
See all $CMPS insider activity →Compass Pathways (CMPS) reported Q2 2026 net loss of $253.8 million, or $1.88 per share, vs $38.4 million, or $0.41 per share, citing noncash warrant fair value adjustments. Cash was $433.3 million at June 30, 2026. The company said COMP360 NDA modules are on track for FDA submission in Q4, with a potential first-half 2027 launch subject to rescheduling.
Investing.com reports Compass Pathways (CMPS) has $433M cash, two Phase 3 positive trials for COMP360, and an NDA expected to be completed in Q4 2026, with a potential H1 2027 FDA approval and launch. Analysts cite a consensus price target of $23.75 versus $13.24. The article highlights key risks including DEA psilocybin rescheduling and possible dilution.
Simply Wall St reports COMPASS Pathways (CMPS) will join the VA PIVOT trial, a multi-site study of its COMP360 therapy in veterans, via a new partnership with the U.S. Department of Veterans Affairs. The article cites CMPS at $13.54, with 7-day return 19.3% and 90-day return 40.31%, plus a shelf registration filing and analyst revenue forecast to $284.9M by July 2029.
Over the past 7 days, alphai's AI scored 2 news stories mentioning CMPS (COMPASS Pathways plc). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent CMPS coverage spans earnings, technology and financial news.
Near-term focus is FDA NDA progress and the rescheduling-dependent launch timeline, with clinical durability and prescriber intent supporting the bull case.
CMPS is treated as a high-variance regulatory option where FDA timing is mostly procedural, but DEA rescheduling is the main swing factor for launch and valuation.
VA partnership adds a high-profile clinical execution and enrollment signal for COMP360, but the article frames valuation as still dependent on Phase III and FDA outcomes.
CMPS is part of the trade journal; the article does not add new CMPS fundamentals.
Near-term upside bias if traders interpret the FDA CDER leadership shift as supportive for psychedelic drug review timelines.
alphai scores every news story that mentions CMPS with an AI model for sentiment and relevance, and aggregates insider trades from COMPASS Pathways plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Compass Pathways (CMPS) reported Q2 2026 net loss of $253.8 million, or $1.88 per share, vs $38.4 million, or $0.41 per share, citing noncash warrant fair value adjustments. Cash was $433.3 million at June 30, 2026. The company said COMP360 NDA modules are on track for FDA submission in Q4, with a potential first-half 2027 launch subject to rescheduling.
7 min readInvesting.com reports Compass Pathways (CMPS) has $433M cash, two Phase 3 positive trials for COMP360, and an NDA expected to be completed in Q4 2026, with a potential H1 2027 FDA approval and launch. Analysts cite a consensus price target of $23.75 versus $13.24. The article highlights key risks including DEA psilocybin rescheduling and possible dilution.
7 min readSimply Wall St reports COMPASS Pathways (CMPS) will join the VA PIVOT trial, a multi-site study of its COMP360 therapy in veterans, via a new partnership with the U.S. Department of Veterans Affairs. The article cites CMPS at $13.54, with 7-day return 19.3% and 90-day return 40.31%, plus a shelf registration filing and analyst revenue forecast to $284.9M by July 2029.
6 min readFriday’s jobs data showed 23,000 fewer jobs in July and May and June payrolls were revised down by 103,000, easing near-term Fed rate pressure. The 10-year Treasury yield fell to 4.64%. The S&P 500 rose 0.6% to a record as Q2 earnings showed near 50% profit growth. The article also lists options trades in NVO, SPCX, PGEN, OSCR, YOU, PLTR, CF, OUST, CMPS, and ATI.
7 min readCompass Pathways (CMPS) shares rose about 16% in pre-market, targeting levels not seen in over two years. The move follows a Trump executive order to speed medical research and treatment access, plus FDA CDER leadership changes. Compass said the FDA granted COMP360 a National Priority Voucher for treatment-resistant depression, and Jefferies estimates 75% to 85% approval odds in FY26.
3 min readCOMPASS Pathways plc (NASDAQ:CMPS) reported a Q2 2026 basic and diluted loss of $1.88 per share versus a $0.41 consensus estimate, a 358.5% miss, and a net loss of $253.8M. Shares rose 4.9% to $11.80. The company is advancing its psilocybin therapy program in Phase 3 trials, according to the report.
3 min readCompass Pathways (Nasdaq: CMPS) reported Q2 and first-half 2026 results and said two Phase 3 trials for COMP360 in treatment-resistant depression showed rapid onset and benefit maintained through at least 6 months. The company is on track for an FDA rolling NDA completion in Q4, with commercial launch expected in H1 2027, subject to approval. Cash was $433 million at quarter end.
7 min readCompass Pathways (CMPS) shares rose about 4.8% after it reported Q2 and first-half 2026 results. The company said it had $433 million cash as of June 30, 2026, enough to fund operations through 2028, and reaffirmed COMP360’s NDA submission in Q4 2026 and U.S. launch in H1 2027, subject to FDA/DEA actions.
3 min readCompass Pathways plc (Nasdaq: CMPS) reported Q2 and first-half 2026 results and said its COMP360 psilocybin for treatment-resistant depression showed rapid onset and benefit through at least 6 months in two Phase 3 trials. The company is pursuing a rolling NDA with Q4 completion and expects launch in H1 2027, subject to FDA approval and DEA rescheduling. Cash was $433 million at quarter end.
7 min readCOMPASS Pathways plc (CMPS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026pressrelease.htm EX-99.1 Document Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights • Data from two positive Phase 3 trials demonstrated rapid onset of effect and durable benefit through at least 6 months, furt
7 min read
